What is Madrigal Pharmaceuticals, Inc.'s SG&A?

Madrigal Pharmaceuticals, Inc. (MDGL) reported SG&A of $46.83M in Q1 2026.

Madrigal Pharmaceuticals, Inc. MDGL SG&A

Revenue$311.3M+127%

Gross profit$43.5M—

Operating income-$92.7M-16.9%

Net income-$94.4M-28.9%

EPS (diluted)-$3.25-24.5%

Cash & equivalents$232.2M+23.1%

Total debt$377.3M+187%

Total equity$543.5M-23.5%

Total assets$1.2B+23.1%

Operating cash flow-$167.4M-88.4%

CapEx$3.8M—

Free cash flow-$171.3M-92.7%

Market cap$11.66B+64.2%

Enterprise value$11.81B+67.5%

P/S10.3×-12.1×

Gross margin96.5%—

Operating margin-27.7%-12.2pp

Net margin-27.3%-12.0pp

FCF margin-59.8%-29.6pp

Return on equity-49.3%-0.8pp

Debt / equity0.7×+0.5×

Current ratio3.5×-2.4×

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept mdgl:AccruedSellingGeneralAndAdministrativeCurrent.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Madrigal Pharmaceuticals, Inc.'s SG&A?: Madrigal Pharmaceuticals, Inc. (MDGL) reported SG&A of $46.83M in Q1 2026.